ABSTRACT OBJECTIVE: Nephrotoxicity has been described in some patients with inflammatory bowel disease (IBD) treated with 5-aminosalicylates (5-ASA). Our aim was to conduct a retrospective study of IBD patients, both with and without 5-ASA treatment, who underwent regular evaluation of renal function over a 4-year period. METHODS: Serum creatinine was measured before the start of 5-ASA therapy, and thereafter yearly up to 4 years. Creatinine clearance (Cl Cr ) was estimated from serum creatinine (Cockroft & Gault formula). The influence of 5-ASA treatment on renal function was assessed by univariate and multivariate analysis. RESULTS: A total of 150 IBD patients (ulcerative colitis in 45%, Crohn's disease in 55%) were included. Sixty-two patients were receiving 5-ASAs (95% coated mesalazine, mean dose 1.9 ± 0.8 g/day). Both serum creatinine levels and Cl Cr were similar in patients with and without 5-ASA treatment, and remained stable throughout the 4-year follow-up in patients taking 5-ASAs. In the multivariate analysis, 5-ASA treatment (or its dose) was not correlated with serum creatinine levels or Cl Cr . No interstitial nephritis was reported during follow-up. CONCLUSION: 5-ASA-related renal disease was not found in our series, suggesting that the occurrence of renal impairment in IBD patients receiving these drugs is exceptional. Our results do not support the recommendation of serum creatinine monitoring in patients receiving 5-ASA treatment.
INTRODUCTION
In mild to moderate active ulcerative colitis, both sulfasalazine and 5-aminosalicylic acid (5-ASA) have proven efficacy in inducing and maintaining clinical remission 1, 2 . Considerations of long-term toxicity are important as lifetime maintenance treatment is usually recommended for ulcerative colitis. The introduction of 5-ASA into the treatment of patients with inflammatory bowel disease (IBD) has offered the opportunity of increasing dosages much further than had been possible with sulphonamide carrier compounds such as sulfasalazine, as a major advantage of 5-ASA agents is the safety profile 2 . However, a number of cases have been reported with 5-ASA-related toxicity 3, 4 . In particular, nephrotoxicity, which may be potentially irreversible, has been described in some patients with IBD treated with 5-ASA [3] [4] [5] . In this respect, both acetylsalicylic acid and phenacetin, which have been implicated in the occurrence of non-steroidal anti-inflammatory drug induced nephropathy, share structural similarities with 5-ASA 6, 7 . Furthermore, it has been demonstrated that 5-ASA may cause lesions to kidney tubular epithelial cells in animals when fed in high doses 6, 7 . The actual incidence of nephrotoxicity in IBD patients receiving 5-ASA therapy has not been determined, but it has been suggested that renal impairment may occur in up to 1 in 100 patients treated with 5-ASA, although clinically important interstitial nephritis would occur in only 1 in 500 patients 8 . However, data regarding potential of renal impairment by 5-ASA therapy are contradictory, with some studies reporting an incidence > 1% of interstitial nephritis, and others suggesting that 5-ASA treatment has no effect on renal function 5 . Nevertheless, these data are based on a relatively low number of patients and with a limited follow-up. Consequently, despite increasing recognition of the potential for this serious adverse event (nephrotoxicity), guidelines for monitoring renal function in patients prescribed 5-ASA preparations are not widely employed 3 . Furthermore, no evidence exists to date that either the test, or the frequency of testing, is effective in identifying these patients at risk of developing 5-ASA-related renal impairment, and therefore there are no firm recommendations for renal function monitoring in IBD patients treated with these drugs. Our aim was to conduct a retrospective study of IBD patients, both with and without 5-ASA treatment, evaluating parameters of renal function regularly analyzed during 4 years, to assess whether long-term use of these drugs has detrimental effects on renal function.
PATIENTS AND METHODS

Patient population
Consecutive patients with the diagnosis of IBD at the Gastroenterology Unit from the Hospital Universitario de la Princesa (Madrid, Spain) and followed-up for at least 4 years, were included in this retrospective study. Diagnoses of Crohn's disease and ulcerative colitis were established by standard clinical, radiological, histological, and endoscopic criteria 9 . The Vienna classification of Crohn's disease based on Age at Diagnosis -under 40 years (A1), equal to or over 40 years (A2)], Location [terminal ileum (L1), colon (L2), ileocolon (L3), upper gastrointestinal (L4)], and Behaviour [nonstricturing nonpenetrating (B1), stricturing (B2), penetrating (B3)-, was used. For ulcerative colitis, a classification based on the location and extension of the disease was used: proctitis, left-side colitis (up to the splenic flexure), and extensive colitis/pancolitis. Exclusion criteria were: pre-existing renal disease, cardiac or hepatic failure, hypertension, diabetes mellitus, patients treated with diuretics or antihypertensive drugs, and the history of chronic ingestion of aspirin or non-steroidal anti-inflammatory drugs.
Data collection
Medical records from these patients were reviewed for the study. At baseline, the following variables were prospectively extracted in a predefined data extraction form: age, sex, smoking habit, body weight, type of IBD, site of involvement, history of bowel resections, and use of medication since the diagnosis (mainly with 5-ASA, but also with other drugs used for the treatment of IBD, and with non-steroidal anti-inflammatory drugs). With respect to the use of 5-ASAs, patients were divided into the following subgroups: patients without a history of 5-ASA treatment, with a history of sulfasalazine, with a history of mesalazine, or with a history of both compounds. 5-ASA dosage was categorized as: low (less than 1.5 g/day), intermediate (more than 1.5 but less than 3 g/day) and high (more than 3 g/day). All data obtained were collected in an anonymous database for the analysis, which was approved by the local Medical Ethical Committee.
Assessment of renal function
Patients were reviewed in our out-patient clinic every 6 months for clinical evaluation of disease activity. Analytical controls (including complete blood count and biochemistry including creatinine) were performed every 12 months in all patients. Renal function was monitored by measuring levels of serum creatinine in all patients (both with and without 5-ASA treatment). In patients taking 5-ASAs, serum creatinine was measured before starting 5-ASA therapy, and thereafter yearly up to 4 years (patients were taking the drug at a stable dose for the 4-year period of study). Because creatinine excretion was not regularly measured, we were unable to calculate endogenous creatinine clearance (Cl Cr ). Therefore, Cl Cr was estimated from serum creatinine with the Cockroft and Gault formula, which takes into account age, weight and sex 10, 11 . The Cl Cr (in ml/min) was calculated by the following formula: (140 -age [in years] ϫ body weight [in kg]/72 ϫ serum creatinine [in mg/100 ml]); because of differences in body composition, a correction factor of 0.85 was used for women. Based on the estimated glomerular filtration rate, patients were classified as having: normal renal function (Cl Cr > 60 ml/min), moderate impairment (Cl Cr 30-59), severe impairment (Cl Cr [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] , and advanced renal failure (Cl Cr < 15) 11 .
Statistical analysis
For continuous variables, mean and standard deviation were calculated. For categorical variables, percentages and corresponding 95% confidence intervals (95% CI) were provided. Categorical variables were compared with the 2 test, and quantitative variables with the Student t test. A p value < 0.05 was considered statistically significant. The influence of 5-ASA treatment on renal function was assessed by multivariate analysis (multiple linear regression analysis). The dependent variable was Cl Cr , and the independent variables were: age (categorized as higher or lower than 42 years, which was the median value), sex (male/female), smoking (smokers/non-smokers), weight (categorized as higher or lower than 67 kg, which was the median value), type of IBD (ulcerative colitis or Crohn's disease), and treatment with 5-ASAs or steroids.
RESULTS
One-hundred and fifty patients (45% with ulcerative colitis and 55% with Crohn's disease) were included in the study. Mean age was 45 ± 15 years, 45% were males, and 30% were smokers. Vienna classification of Crohn's disease patients was as follows: age at diagnosis (A1, 79%; A2, 21%), location (L1, 25%; L2, 20%; L3, 51%; and L4, 4%), and behaviour (B1, 43%; B2, 21%; and B3, 36%). Ulcerative colitis location distribution was as follows: proctitis (25%), left-side colitis (43%), and extensive colitis/pancolitis (32%). 
, and 2 patients (3.2%) received sulfasalazine. Mean dose of mesalazine was 1.9 ± 0.8 g/day (range, 0.5-4), and most patients were receiving between 1 and 3 g/day (< 1 g/day, 4 patients; 1-2 g/day, 21 patients; 2-3 g, 22 patients; and 3-4 g/day, 8 patients). Sixty-three patients were receiving azathioprine or mercaptopurine, and 3 patients were treated with infliximab. (table I) . The percentage of patients with moderate impairment of the estimated glomerular filtration rate at 0, 1, 2, 3, and 4 years was: 16.1% (95% CI, 9-27), 14.5% (7.8-25%), 12.9% (6.7-23%), 14.5% (7.8-25%), and 3.2% (0.9-11) (fig. 3) ; while the corresponding figure for severe impairment of the estimated glomerular filtration rate was 0% at all control times ( fig. 3) . Finally, in the multivariate analysis, 5-ASA treatment (yes/no) did not correlate with serum creatinine levels or Cl Cr . Dose of 5-ASA was not predictive for change in renal function. No interstitial nephritis was reported during follow-up.
DISCUSSION
5-ASA-related renal disease was not reported in our series, which suggests that the incidence of renal impairment in IBD patients receiving these drugs is exceptional. formed in 1995, two patients (1.3%) developed modest, reversible renal impairment, only one of whom had biopsy proven interstitial nephritis (which represents a rate of clinically significant interstitial nephritis of approximately 1 in 150 12 ). In 1996, a review of eight published clinical trials of 5-ASA therapy in IBD concluded that renal impairment, defined as any increase in serum creatinine, may occur in up to 1 in 100 patients treated with this drug, but that the incidence of clinically significant interstitial nephritis was less than 1 in every 500 patients treated 8 . This same year, Marteau et al 13 presented the safety reports on the use of Pentasa in France: spontaneous reports of adverse effects, submitted to a pharmaceutical manufacturer over a 2-year period, included 2 cases of renal impairment in approximately 45,000 patient-years of therapy 13 . One year later, Walker et al 14 17 , in a large epidemiological study in the UK, included almost 40,000 patients and found that the overall incidence of renal damage was rare in patients taking 5-ASA drugs, but was increased relative to control patients (general population). More recently, data from the UK General Practice Research Database showed an incidence rate of 0.17 cases per 100 patients per year 18 . At the same time, in 2004, in a large European registry containing more than 1,500 patients with IBD, reported during a follow-up of 1 year, the incidence of renal failure was not increased in patients using 5-ASA 19 . Finally, a detailed postal questionnaire sent in 2004 to members of the British Society of Gastroenterology and the Renal Association 20 , calculated an incidence of 5-ASA nephrotoxicity of 1 in 4,000 patients/year only. The renal impairment associated to 5-ASA use may be diagnosed at any interval after starting treatment. Thus, several studies have concluded that there is no relationship between duration of 5-ASA treatment and the risk of renal disease 15, 21 , and that nephrotoxicity may appear from less than 1 month to more than 80 months after starting 5-ASA treatment 5 . However, most studies have included a relatively low number of patients and with a limited follow-up (of only several months). In our study, serum creatinine levels remained stable in patients taking 5-ASAs during the 4-year follow-up. Similarly, Cl Cr did not change in these 4 years in 5-ASA treated patients, and no interstitial nephritis was reported during follow-up. Studies with 5-ASA treatment in which serum creatinine or Cl Cr was measured regularly are summarized in table  II 12,21-51 -including a total of 2,671 patients receiving 5-ASA treatment during a total of 3,070 years of followup-, where it is shown that nephrotoxicity was exceptional, being reported in only a few studies 12, 22, 43 (giving a mean annual nephrotoxicity rate of only 0.26% per patient-year of follow-up) 5 . There have been several case reports of renal disease associated with 5-ASA treatment in patients with IBD (table III) 8, . The actual development of 5-ASA-related renal disease seems rare, as only 46 patients with this complication have been reported 5 . Thus, although the association between 5-ASA therapy and tubulo-interstitial nephritis is clearly described in several case reports, our study and other studies came to the reassuring conclusion that renal impairment in IBD patients is not frequently observed and is rarely associated with 5-ASA therapy. In the study by Elseviers et al 19 , all IBD patients seen at the outpatient clinic of 27 European centres of gastroenterology during 1 year were registered and screened for renal impairment controlling for a possible association with 5-ASA therapy. Renal screening (calculated Cl Cr ) was performed at baseline, after 6 and 12 months. 49 1.5 0 (0%) Singleton et al 49 
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> 6 0 (0%) Thomson et al 51 
68
without renal impairment, no difference could be observed in 5-ASA consumption. In our study, dosage of 5-ASA was not predictive for change in renal function. In pre-clinical studies in animals nephrotoxicity appeared to be dose-related 3 . However, interstitial nephritis has been reported in patients taking doses of 5-ASA as low as 0.75 g/day 81 or even 0.5 g/day 65 . Most of the cases of nephrotoxicity reported in the literature occurred in patients taking doses from 1.2 to 2.4 g/day, being relatively low 5 . Furthermore, several studies have concluded that there is no relationship between 5-ASA dose and the risk of renal disease 15, 18, 19, 21, 24 . Finally, some authors have evaluated urinary enzymes as markers of renal tubular damage in patients with IBD, and could not demonstrate a correlation between the enzymuria and the cumulative doses of 5-ASA 84 . Moreover, they showed normalization of these urinary enzymes with successful medical therapy (directed to IBD) despite increasing cumulative doses of 5-ASA 84 . In this respect, in a point prevalence study no clear distinction between the influence of disease activity and drug treatment can be made, if increased dosage of the anti-inflammatory drug used correlates highly with disease activity 47 . The low overall incidence of renal disease during 5-ASA treatment reported in the literature, together with the absence of a clear relationship between 5-ASA dose and the risk of nephrotoxicity, suggest that the renal reactions may be idiosyncratic rather than dose related in nature. Our study has several methodological limitations. Firstly, its retrospective design, although the study variables were prospectively extracted in a predefined data extraction form. Secondly, renal function was monitored by measuring levels of serum creatinine. The shortcomings of serum creatinine as a marker of renal function are well-known, and this parameter is a poor marker of renal function despite its universal use for this purpose. It is significantly af- fected by a range of factors unrelated to glomerular filtration rate (e.g. sex, muscle mass and dietary meat intake) 85 . Furthermore, significant loss of functioning renal mass may occur before any rise in serum creatinine is apparent 85 . Therefore, more studies are necessary to determine whether serum creatinine gives sufficient warning of nephrotoxicity or whether more elaborate tests of renal function are required 20 . Because creatinine excretion was not regularly measured, we were unable to calculate endogenous Cl Cr . However, in coincidence with other studies 19, 24 , Cl Cr in our patients was estimated from serum creatinine with the Cockroft and Gault formula, which takes into account age, weight, and sex 10, 11 . The above formula gives a correlation coefficient between predicted and mean measured Cl Cr of 0.83, a figure that, although relatively high, is not perfect 10 . With this formula, the mean Cl Cr may be estimated reliably in groups of patients. However, in higher ranges of Cl Cr , the formula seems to underestimate Cl Cr , whereas Cl Cr seems to be overestimated in lower ranges 3, 11 . Finally, due to the low incidence of 5-ASA related nephrotoxicity, thousands of patients would be needed to observe any significant difference between exposed and non-exposed subjects 86 . Thus, analytical epidemiological research (prospective cohort study or case-control study) needs the inclusion of a very large number of IBD patients. It has been emphasized the need for timely recognition of renal impairment and prompt discontinuation of 5-ASA treatment of affected patients. By not doing so, patients are placed, in theory, at risk for developing irreversible kidney damage. Thus, despite a lack of evidence that monitoring of serum creatinine is necessary or effective in patients receiving 5-ASA treatment, it has been suggested that there is a need for this analytical control. However, the optimal monitoring schedule remains to be established as there is no evidence to date that either the test, or the frequency of testing, is effective in identifying these patients at risk of developing 5-ASA-related renal impairment. Therefore, there are no firm recommendations, supported by medical evidence, for renal function monitoring (type and frequency) in IBD patients treated with these drugs 5 . Consequently, the «recommendations» regarding systematic screening for renal impairment should be considered as being «suggestions» and not as medically necessary based upon the review of the literature, as there is presently no evidence that such screening or monitoring improves patient outcomes 5 .
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